255 related articles for article (PubMed ID: 16766048)
1. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
Offermanns S
Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048
[TBL] [Abstract][Full Text] [Related]
2. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.
Lukasova M; Hanson J; Tunaru S; Offermanns S
Trends Pharmacol Sci; 2011 Dec; 32(12):700-7. PubMed ID: 21944259
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic acid: pharmacological effects and mechanisms of action.
Gille A; Bodor ET; Ahmed K; Offermanns S
Annu Rev Pharmacol Toxicol; 2008; 48():79-106. PubMed ID: 17705685
[TBL] [Abstract][Full Text] [Related]
4. Future of GPR109A agonists in the treatment of dyslipidaemia.
Wanders D; Judd RL
Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
[TBL] [Abstract][Full Text] [Related]
5. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G).
Tunaru S; Lättig J; Kero J; Krause G; Offermanns S
Mol Pharmacol; 2005 Nov; 68(5):1271-80. PubMed ID: 16099840
[TBL] [Abstract][Full Text] [Related]
6. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
Pike NB
J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
[TBL] [Abstract][Full Text] [Related]
7. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
8. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
Tang H; Lu JY; Zheng X; Yang Y; Reagan JD
Biochem Biophys Res Commun; 2008 Oct; 375(4):562-5. PubMed ID: 18722346
[TBL] [Abstract][Full Text] [Related]
9. Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug?
Pike NB; Wise A
Curr Opin Investig Drugs; 2004 Mar; 5(3):271-5. PubMed ID: 15083592
[TBL] [Abstract][Full Text] [Related]
10. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
Mahboubi K; Witman-Jones T; Adamus JE; Letsinger JT; Whitehouse D; Moorman AR; Sawicki D; Bergenhem N; Ross SA
Biochem Biophys Res Commun; 2006 Feb; 340(2):482-90. PubMed ID: 16389067
[TBL] [Abstract][Full Text] [Related]
11. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
12. New evidence for nicotinic acid treatment to reduce atherosclerosis.
Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F
Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in the discovery of niacin receptor agonists.
Semple G; Boatman PD; Richman JG
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):452-9. PubMed ID: 17659487
[TBL] [Abstract][Full Text] [Related]
14. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.
Tunaru S; Kero J; Schaub A; Wufka C; Blaukat A; Pfeffer K; Offermanns S
Nat Med; 2003 Mar; 9(3):352-5. PubMed ID: 12563315
[TBL] [Abstract][Full Text] [Related]
15. Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin.
Hanson J; Gille A; Offermanns S
Pharmacol Ther; 2012 Oct; 136(1):1-7. PubMed ID: 22743741
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic acid: an old drug with a promising future.
Bodor ET; Offermanns S
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S68-75. PubMed ID: 18037924
[TBL] [Abstract][Full Text] [Related]
17. HM74a agonists: will they be the new generation of nicotinic acid?
Martres P
Curr Top Med Chem; 2009; 9(5):428-35. PubMed ID: 19519459
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.
Shen HC; Ding FX; Deng Q; Wilsie LC; Krsmanovic ML; Taggart AK; Carballo-Jane E; Ren N; Cai TQ; Wu TJ; Wu KK; Cheng K; Chen Q; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
J Med Chem; 2009 Apr; 52(8):2587-602. PubMed ID: 19309152
[TBL] [Abstract][Full Text] [Related]
19. Nicotinic acid receptor subtypes and their ligands.
Soudijn W; van Wijngaarden I; Ijzerman AP
Med Res Rev; 2007 May; 27(3):417-33. PubMed ID: 17238156
[TBL] [Abstract][Full Text] [Related]
20. Novel patent publications on high-affinity nicotinic acid receptor agonists.
Shen HC; Colletti SL
Expert Opin Ther Pat; 2009 Jul; 19(7):957-67. PubMed ID: 19552512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
